PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy

Immunotherapy with PD-1/PD-L1-blocking antibodies is clinically effective for several tumor types, but the mechanism is not fully understood. PD-L1 expression on tumor biopsies is generally regarded as an inclusion criterion for this cancer therapy. Here, we describe the PD-L1-blocking therapeutic r...

Descripción completa

Detalles Bibliográficos
Autores principales: Kleinovink, Jan Willem, Marijt, Koen A., Schoonderwoerd, Mark J. A., van Hall, Thorbald, Ossendorp, Ferry, Fransen, Marieke F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414865/
https://www.ncbi.nlm.nih.gov/pubmed/28507803
http://dx.doi.org/10.1080/2162402X.2017.1294299

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414865/
https://www.ncbi.nlm.nih.gov/pubmed/28507803
http://dx.doi.org/10.1080/2162402X.2017.1294299

Ejemplares similares